NICE To Recommend AZ's Lynparza After All
This article was originally published in Scrip
AstraZeneca has managed to provide the necessary evidence for NICE, the health technology appraisal institute for England and Wales, to say yes to its PARP inhibitor Lynparza (olaparib) for a patient subpopulation with BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer. Earlier this year NICE looked set to reject the drug.
Register for our free email digests: